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Interleukin-lb induces gene expression and secretion of the secretory phospholipase A, (sPLA,) and prostaglandin E2 (PGE3 release from rat 
mesangial cells. We have previousy shown that prolonged treatment of rat mesa&al cells with interleukin-l/I (IL-l@) also enhances the cytosolic 
phospholip~e A, (cPLA,) activity. This effect of IL-l/3 on the cPLA, activity is inhibited by actinomy~in D and cy~lohe~ide, ~~cat~g that 
both transcription and translation are involved. Here, we describe that IL-l/S increases mRNA levels and protein synthesis of cPLA, itself. In parallel 
with the effect of dexamethasone on the sPLA,, this glucocorticoid inhibits the IL-lj%enhanced cPLA, activity as a result of the suppression of 
IL-l/I-induced cPLA, gene expression. This report suggests that the pro-inflammatory action of interleukin-l/I may, in part, be mediated by its 
effects on cPLA, activity. 
Phospholipa~ A,; Interleukin-1~; Dexamethasone; Rat mesangial cell 
1. INTRODUCTION 
Interleukin- l/3 (IL- 18) is a potent pro-inflammatory 
cytokine produced mainly by stimulated macrophages 
and monocytes [l]. IL-lp shows a wide variety of bio- 
logical activities. It plays an important role in the medi- 
ation of infla~ato~ responses. Stimulation of target 
cells with IL-IS enhances the production of inflamma- 
tory mediators, in particular prostaglandins, leukotri- 
enes and platelet-activating factor. It is now well estab- 
lished that activation of PLAl is the key controlling 
event in the synthesis of these inflammatory mediators. 
PLA,s are a diverse family of enzymes which catalyze 
the hydrolysis of the 2-acyl ester bond of phospholipids. 
The action of PLA, is of particular interest for the re- 
lease of arachidonic acid, which serves as a the rate- 
limiting step for the biosynthesis of the eicosanoids [2]. 
ever, despite recent progress it is presently still unclear 
which PLA,s are involved in the release of arachidonic 
acid during inflammatory diseases. 
Mammalian cells contain several PLA2 enzymes, in- 
cluding the 14 kDa secretory PLAz (sPLA,) and the 
recently described cytosolic PLA, (cPLAJ [3,4]. The 
role of the sPLA, in infla~ation has recently been 
reviewed by Vadas and Pruzanski [53. The cPLA, is 
found in a variety of cell types and selectively cleaves 
arachidonic acid from phospholipids [6]. In several cell 
lines it has been shown that cPLA, is coupled to 
ho~one-indu~d arachidonic acid release [7,8]. How- 
Glomerular mesangial cells are one of the target cells 
for potent inflammatory cytokines. Both sPLA, and 
cPLA, have been described in rat mesangial cells [7,9]. 
We and others have recently shown that IL-l@ and 
tumor necrosis factor (TNT;) enhanced the synthesis 
and secretion of the sPLA, and PGE*, which was ac- 
companied by increased mRNA levels coding this PLA, 
in rat mesangial cells [9-121. Such observations have 
also been made in other cell types [I 3-161. In addition, 
we have recently shown that prolonged treatment of rat 
mesangial cells with IL-lp and transforming growth 
factor-p2 enhanced the cPLA, activity [17]. Whether the 
increased cPLA, activity was associated with a de novo 
synthesis rather than an activation by enzyme modifica- 
tion was not established. IL-I was also shown to induce 
the accumulation of cPLA, and the release of PGE2 in 
human fibroblasts [18] and rheumatoid synovial fibro- 
blasts [19]. However, in contrast to rat mesangial cells, 
the sPLA, was not affected in fibroblasts. Furthermore, 
TNF induced cPLA, activity in human epithelial carci- 
noma cells [20], HeLa cells[21] and a human endothelial 
cell line [22]. 
*Corresponding author. Fax: (31) (30) 522 478. 
Abbreviations: 11-l& interleukin-l,f?; cPLA,, cytosolic phospholipase 
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It has been shown that the cyto~ne-indu~d cPLA, 
activity can be inhibited by glucocorticoids [l&20]. We 
have shown previously that the cytokine-induced ex- 
pression of sPLA, in rat mesangial cells was prevented 
by dexamethasone 2231. However, the effect of dexa- 
methasone on the cPLA, activity has not yet been eluci- 
dated in rat mesangial cells. In the present study, we 
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show that IL-l/I increased cPLA, mRNA levels and 
cPLA, mass in rat mesangial cells, resulting in enhanced 
cPLA, activity. This IL- l/%-induced de novo synthesis of 
the cPLA,is completely suppressed by dexamethasone. 
2. MATERIALS AND METHODS 
2.1. Mare&Is 
Recombinant IL-l/I was prepared by the Biotechnology Depart- 
ment of Ciba-Geigy Ltd., Basel, Switzerland. 1-Stearoyl-2-[1-“‘Clara- 
chidonoylphosphatidylcholine, deoxycytidine 5’-[a-‘*P]triphosphate 
([a-32P]dCTP, 3,000 Ciimmol) and [‘?Z]methionine and -cysteine were 
obtained from Amersham International, UK. The random primer 
labeling kit was from Boehringer-Mannheim, Germany. The PGE, 
assay kit and the nylon membranes (GeneScreen) were purchased 
from New England Nuclear, Boston, USA. Rabbit anti-cPLA, anti- 
body was kindly donated by Dr. J. Clark, Genetics Institute, Boston, 
USA. A cDNA probe for mouse cPLA, comprising residues 529-2,390 
was provided by Dr. R.M. Kramer, Lilly Research Laboratories, 
Indianapolis, USA. 
2.2. Cell culture and incubation 
Mesangial cells were cultivated and characterized as described pre- 
viously [24] with slight modifications. The cells were grown in RPM1 
1640 supplements with 14% fetal calf serum, penicillin (10 IUlml), 
streptomycin (lO,@ml) and insulin (0.13 W/ml). The cells were main- 
tained in an incubator at 37°C in an atmosphere of 92.5% air and 7.5% 
CO*. Cells were passaged using split ratios of 4-5 at 3-5 day intervals. 
For the experiments only cells up to passage 30 were used. Confluent 
mesangial cells cultured in 25 cm2 tissue culture flasks were washed 
once with PBS and incubated with 5 ml of RPM1 1640 containing 0.1 
mg/ml of fatty acid-free bovine serum albumin with or without IL-l/l 
for 24 h. After the indicated time periods, the su~~atant was re- 
moved and stored at -40°C until further analysis for PGE, forma- 
tion. 
2.3. Preparation of cytosolic fractions 
After incubation and withdrawal of the supernatant, he cells were 
washed once with PBS and scraped with a plastic policeman into 0.5 
ml of homogenization buffer: 50 mM HEPES, pH 7.4,0.25 M sucrose, 
1 mM EDTA, 1 mM EGTA, 50pM sodium fluoride, 10pM leupeptin, 
0.15 mM phenylmethanesulfonyl fluoride. The cells were homoge- 
nized with 10 strokes using a Potter-Elvehjem motor-driven Teflon 
pestle at 600 rpm. The homogenate obtained was then centrifuged at 
2~,~ x g for 30 min in a Beckman TL-100 Ultracent~fuge with a 
TLA 100.3 rotor. The resulting supernatant was designated the cy- 
tosolic fraction. 
2.4. Assays 
The cPLA, enzymatic activity was measured with 2.5 PM 1-Stea- 
royl-2-[l-‘4C]arachidonoylphosphatidylcholine as substrate in 0.2 ml 
ofO.1 M Tris-HCl, pH 8.5, containing 1 mM CaCl, in excess of EGTA 
and EDTA and 5 mM DTT to inactivate the sPLA,. After incubation 
for 5 min at 37°C the reaction was stopped and the released 
[I-Wlarachidonate was extracted by a modified Dole extraction pro- 
cedure [25]. 
Protein con~ntrations were determined with a Bio-Rad protein 
assay solution with bovine serum albumin as standard. 
PGE, was determined by a radioimmunoassay. 
For immunopr~ipitation of cPLA,, mesangial cells were harvested 
and lysed in RIPA-buffer: 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
1 mM EGTA, 1 mM EDTA, 1 mM PMSF, 1% sodium deoxycholate 
and 0.1% Triton X-100. The lysates were clarified by centrifugation 
at 14,000 x g for 10 min. After a pre-clearance step with pre-immune 
serum, the cPLA, was isolated from the lysates by immunoprecipita- 
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tion using 3 ~1 of rabbit anti-cPLA, antibody. After incubation at 4°C 
overnight, the antigen-antibody complex was bound to 6.5 mg protein 
A-Sepharose. The i~unopr~ipitates were washed once with the 
RIPA buffer and twice with 20 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 
1% T&on X-100 and twice with 20 mM Tris-HCl pH 7.4, 0.15M 
NaCI, 1% Triton X-100. The samples were boiled for 3 min in 30 ~1 
Laemmli’s sample buffer and applied to SDS-PAGE (10% gel). 
2.6. Northern blot analysis 
Total mesangial cell RNA was extracted using the guanidinium 
~iocyanate/pheno~chlorofo~ method [26]. RNA (20 ,ug) was sepa- 
rated on 0.8% agarose gels containing 6.6% formaldehyde and trans- 
ferred to GeneScreen membranes. The filters were baked at 80°C for 
2 h and prehybridized at 42°C in 50% (vlv))formamide, 10% (w/v) 
dextrane sulphate, 1% SDS (w/v), 1 M NaCl and 100 &ml denatu- 
rated herring sperm DNA. The filters were hybridized at 42’C over- 
night with a cDNA probe coding for mouse cPLA2, comprising resi- 
dues 529-2,390, and labeled with [a-32P]dCTP according to the 
random primer labeling technique described by Feinberg and Vogel- 
stein [27]. After washing, the signal was detected by autoradiography. 
3. RESULTS AND DISCUSSION 
As illustrated in Fig. 1, prolonged treatment of rat 
mesangial cells with IL-l/? enhanced the cPLA, activity 
3-fold. The cPLA, activities were measured in the pres- 
ence of DTT to inactivate the sPLA, completely [17]. 
The stimulation of the cPLA, by IL-l/I was completely 
blocked by actinomycin D and cycloheximide, de- 
monstrating that synthesis of RNA and new protein is 
involved in IL-@-enhanced cPLA, activities. The effect 
of IL-l/3 on the cPLA, is a~ompanied by the effect of 
IL-l/3 on PGE, synthesis. IL-l/I treatment of mesangial 
cells resulted in a IOO-fold increase in the formation of 
PGE2. These results are in agreement with previously 
observed data [10,17]. Similar results were also reported 
for IL-l -stimulated fibroblasts [ 18,191. However, in 
contrast to what was shown in fibroblasts, IL-l@ also 
induced the synthesis and secretion of sPLA, in rat 
mesangial cells [9]. Thus, both PLA,s could be involved 
in the IL-l/I-induced release of arachidonate for the 
observed PGE, fo~ation. The relative cont~butions of 
both IL-lp-induced sPLA, and cPLA2 activities in the 
release of arachidonate for the enhanced synthesis of 
PGEz in rat mesangal celis remains to be established. 
Recently, we provided evidence that an enhanced 
cPLA, activity is involved in transforming growth fac- 
tor-/32-induced PGEz synthesis in rat mesangial cells 
~791. 
Glucocorticosteroids are widely used anti-inflamma- 
tory drugs. The anti-intlammatory activity has been at- 
tributed to their ability to inhibit prostaglandin synthe- 
sis. The contribution of sPLA, to PGEI! formation is 
supported by the dose-dependent inhibition of IL-ljI- 
induced sPLA, and PGE, synthesis by dexamethasone 
in rat mesangial cells 1231. However, the effect of dexa- 
methasone on the cPLA, activity has not been eluci- 
dated in rat mesangial cells so far. Therefore, we started 
to determine the effect of dexamethasone on the IL- I/% 
enhanced cPLA, activity. As shown in Fig. 2, the IL-l/% 
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Fig. 1, Effect of actinomycin D and cycloheximide on IL-l&enhanced cPLAt activity and PGE, release from rat mesa&al cells. Rat mesangial 
cells were incubated with actinomycin D (10 PM) or cycloheximide (10 PM) alone or together with IL-l/I (1 nM) for 24 h. Thereafter, 200 ,~l of 
the culture supematants were used for PGEz measurements. Cytosolic fractions of the cells were prepared and measurements of the cPLA, activities 
were done as described in section 2. Results are means f S.E.M. from triplicate experiments. 
induced cPLA, activity was dose-dependently inhibited 
by dexamethasone with a complete inhibition at 100 
nM. 
In order to determine whether the IL-l/?-enhanced 
cPLA, activity was directly due to increased cPLA, 
mass levels or indirectly to the synthesis of proteins 
involved in the cPLA, activation, an immunoblot exper- 
iment using cPLA, antibodies was performed. With im- 
munoprecipitation experiments using polyclonal anti- 
bodies raised against a mouse cPLA,, 89% of the cPLA, 
activity could be precipitated, indicating that the anti- 
bodies are cross-reactive with the rat cPLA,. However, 
we could not detect cPLA, protein with Western blot 
analysis, neither in control cells nor in stimulated cells 
(data not shown). This was probably due to the low 
amount of the cPLA, in rat mesangial cells (compare 
also Fig. 4A and B). To study the biosynthesis of the 
cPLA,, rat mesangial cells were stimulated with or with- 
out IL-l/J. In the presence of [3’S]methionine and 
[35S]cysteine. The detection of the cPLA, was done by 
an i~unoprecipitation with a cPLA, antibody, fol- 
lowed by SDS-PAGE and autoradiography (Fig. 3). 
Under these experimental conditions, treatment of rat 
mesangial cells with IL-l/I for ‘24 h was associated with 
approximately a 2-fold increase in cPLA2 protein, as 
estimated by densitometrical scanning. The increased 
cPLA, protein levels correlate with the increased cPLA, 
activity, indicating that the increased cPLA, activity 
upon treatment of mesangial cells with IL-I/? is due to 
increased synthesis of the cPLA,. Similar results have 
been noted for IL-la-treated human fibroblasts 1181, 
macrophage colony stimulating factor-treated human 
monocytes [30] and TNF-treated HeLa cells [21]. 
Next we determined the effect of dexamethasone on 
the induced synthesis of the cPLA,. As shown in Fig. 
3, the IL-l/3 induction of cPLA, protein was prevented 
by treatment of the mesangial cells with dexa- 
methasone. Together with the above mentioned effect 
of dexamethasone on the sPLA,, these observations 
imply that the inhibition of the IL-lB-induced PGE, 
synthesis by dexamethasone in rat mesangial cells is 
caused by direct inhibition of PLA, protein expression. 
IL-l@ (nM) 1 1 1 1 
DEXA (nM) 0 10 102 103 
Fig. 2. Do~de~nd~t i~ibition by dex~ethasone of the cPLA* 
activity upon stimulation of mesangial cells. Rat mesangial cells were 
treated with IL-IS (1 nM) and with dexamethasone atvarious concen- 
trations and 24 h. The cPLA, activities were determined in the cy- 
tosolic fractions as described in section 2. 
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Fig. 3. Effect of IL-l/l and dexamethasone on the cPLA, protein levels 
in rat mesangial cells. Rat mesangial cells were labeled with 
[3SS]methionine and [%]cysteine for 24 h in the presence of IL-18 
(1 nM) or IL-l/l (1 nM) plus dexamethasone (100 nM) as indicated. 
After immunoprecipitation and SDS-PAGE, the cPLA, was detected 
by autoradiography as described. 
The inhibition of the IL-l&induced PGE, synthesis by 
dexamethasone is probably not due to induced synthesis 
of PLA, inhibitory proteins such as annexins. In addi- 
tion, we have recently shown that annexins I-VI are not 
induced by dexamethasone in rat mesangial cells 
(Vervoordeldonk, M. et. al, manuscript submitted). 
These data indicate that dexamethasone interferes with 
arachidonate release by repressing the IL-@-induced 
expression of the sPLA, and cPLA, rather than by in- 
ducing the synthesis of PLA, inhibitory proteins. 
The effect of IL-l/? on the expression of the cPLA, 
was also tested by Northern blot analysis using a cPLAz 
probe. As shown in Fig. 4A, low levels of mRNA are 
present in growing rat mesangial cells. We included 
mouse 3T3 fibroblast mRNA as a positive control. The 
amount of cPLA, activity in 3T3 fibroblasts is ap- 
proxomately 40-fold higher compared to rat mesangial 
cells (Fig. 4B), and this is accompanied by high mRNA 
A 
mRNAcPLA, - 
Fig. 4. (A) Effect of IL-l/? and dexamethasone on the cPLAZ mRNA 
levels in rat mesangial cells. Total RNA (20 fig) of growing rat me- 
sangial cells, serum-starved rat mesangial cells, serum-starved rat me- 
sangial cells treated with IL-lb and serum-starved rat mesangial cells 
treated with both IL-l/? and dexamethasone were analyzed by North- 
ern blotting as described in section 2. As a positive contol we included 
RNA from 3T3 mouse fibroblasts. (B) The cPLA, activities of growing 
rat mesa&al cells and 3T3 fibroblasts. Cytosolic fractions of these 
cells were prepared and measurements of the cPLA, activities were 
done as described in section 2. Results are means f SE from triplicate 
experiments. 
levels (Fig. 4A). In serum-starved rat mesangial cells, no 
mRNA coding for cPLA, could be detected. Treatment 
of such cells with IL-l#? was associated with induced 
cPLA, mRNA levels. The IL-lj?-induced expression of 
the cPLA, gene occurred in paralleled with an increase 
in cPLA, protein levels (Fig. 3) 
In summary, our studies provide evidence that the 
pro-inflammatory mediator, IL-l/?, induces gene ex- 
pression of the sPLA, and the cPLA, and the formation 
of PGE, in rat mesangial cells. The relative contribution 
of these PLA,s for PGE, formation remains to be stud- 
ied in order to establish the physiological role of these 
PLA,s in the progression of renal inflammatory dis- 
eases. 
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